BR112013006769A2 - combinação sinérgica de um anticorpo específico para cd38 - Google Patents

combinação sinérgica de um anticorpo específico para cd38

Info

Publication number
BR112013006769A2
BR112013006769A2 BR112013006769A BR112013006769A BR112013006769A2 BR 112013006769 A2 BR112013006769 A2 BR 112013006769A2 BR 112013006769 A BR112013006769 A BR 112013006769A BR 112013006769 A BR112013006769 A BR 112013006769A BR 112013006769 A2 BR112013006769 A2 BR 112013006769A2
Authority
BR
Brazil
Prior art keywords
specific antibody
synergistic combination
antibody
combination
synergistic
Prior art date
Application number
BR112013006769A
Other languages
English (en)
Other versions
BR112013006769B1 (pt
Inventor
Christofer Samuelsson
Jan Endell
Lisa Rojkjaer
Mark Winderlich
Rainer Boxhammer
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of BR112013006769A2 publication Critical patent/BR112013006769A2/pt
Publication of BR112013006769B1 publication Critical patent/BR112013006769B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

combinação sinérgica de um anticorpo específico para cd38. a presente revelação descreve uma combinaçao farmacêutica de um anticorpo anti-cd38 e lenalidomida e uma combinação farmacêutica de um anticorpo anti-cd38 e bertezomide.
BR112013006769-1A 2010-09-27 2011-09-26 combinação sinérgica BR112013006769B1 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US38661910P 2010-09-27 2010-09-27
EP10180485.4 2010-09-27
US61/386,619 2010-09-27
EP10180485 2010-09-27
US201161437696P 2011-01-31 2011-01-31
US61/437,696 2011-01-31
US201161468607P 2011-03-29 2011-03-29
US61/468,607 2011-03-29
US201161486814P 2011-05-17 2011-05-17
US61/486,814 2011-05-17
PCT/EP2011/066648 WO2012041800A1 (en) 2010-09-27 2011-09-26 Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl

Publications (2)

Publication Number Publication Date
BR112013006769A2 true BR112013006769A2 (pt) 2016-07-05
BR112013006769B1 BR112013006769B1 (pt) 2021-02-02

Family

ID=43640677

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013006769-1A BR112013006769B1 (pt) 2010-09-27 2011-09-26 combinação sinérgica

Country Status (22)

Country Link
US (4) US8877899B2 (pt)
EP (1) EP2621531B8 (pt)
JP (2) JP6087283B2 (pt)
KR (1) KR101912957B1 (pt)
CN (1) CN103118706B (pt)
AU (1) AU2011310696B2 (pt)
BR (1) BR112013006769B1 (pt)
CA (1) CA2812631C (pt)
DK (1) DK2621531T3 (pt)
ES (1) ES2617446T3 (pt)
HU (1) HUE031956T2 (pt)
IL (1) IL224915A (pt)
LT (1) LT2621531T (pt)
MX (1) MX350540B (pt)
NZ (1) NZ607473A (pt)
PL (1) PL2621531T3 (pt)
PT (1) PT2621531T (pt)
RU (1) RU2595839C2 (pt)
SG (1) SG188345A1 (pt)
SI (1) SI2621531T1 (pt)
WO (1) WO2012041800A1 (pt)
ZA (1) ZA201301232B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3284756B1 (en) 2005-10-12 2021-05-05 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN103118706B (zh) 2010-09-27 2016-05-18 莫佛塞斯公司 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
MX368288B (es) * 2012-09-25 2019-09-27 Morphosys Ag Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
WO2014068114A1 (en) * 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
US10342869B2 (en) * 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
SG10201707464SA (en) * 2013-03-13 2017-10-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
EP3677591B1 (en) 2013-04-29 2022-12-28 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP3104882B1 (en) * 2014-02-14 2019-06-05 Centrose, Llc Extracellular targeted drug conjugates
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA119352C2 (uk) * 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10106620B2 (en) 2014-06-16 2018-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells
CR20170086A (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinación con anticuerpos anti-cd38
MX2017005481A (es) 2014-10-29 2017-10-26 Teva Pharmaceuticals Australia Pty Ltd Variantes de interferon a2b.
CA2969717A1 (en) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
CN113527495A (zh) * 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
PT3294769T (pt) * 2015-05-13 2021-04-13 Morphosys Ag Tratamento para mieloma múltiplo (mm)
CN108136218B (zh) 2015-05-20 2022-12-13 詹森生物科技公司 用于治疗轻链淀粉样变性及其它cd38阳性血液恶性肿瘤的抗cd38抗体
JP6816038B2 (ja) 2015-06-22 2021-01-20 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体及びサバイビン阻害剤による血液悪性疾患の併用療法
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
RU2748620C2 (ru) 2015-07-16 2021-05-28 Инхибркс, Инк. Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
CN105079776B (zh) * 2015-09-17 2018-09-21 中南大学 一种石蒜碱和硼替佐米组合物的药物用途
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA53356B1 (fr) 2015-11-03 2022-05-31 Janssen Biotech Inc Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
KR102427948B1 (ko) 2016-03-04 2022-08-02 모르포시스 아게 다발성 골수종에서 m-단백질 반응의 임상 평가
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CA3079242A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2020046767A1 (en) * 2018-08-26 2020-03-05 Trovagene, Inc. Plk1 target phosphorylation status and treatment of cancer with plk1 inhibitors
WO2020250033A1 (en) 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Combination therapies using cd-38 antibodies
WO2022112469A1 (en) 2020-11-27 2022-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring of toxic epidermal necrolysis
TW202309075A (zh) * 2021-04-30 2023-03-01 美商亞得捷歐治療公司 對冠狀病毒s蛋白質具特異性之化合物及其用途
WO2023059900A2 (en) * 2021-10-08 2023-04-13 Invivyd, Inc. Pharmaceutical formulations comprising anti-coronavirus s protein antibodies and uses thereof
WO2024069240A2 (en) * 2022-09-29 2024-04-04 Takeda Pharmaceutical Company Limited Cd38-binding fusion protein combination therapy

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
DE19933130A1 (de) 1999-07-19 2001-01-25 Giesecke & Devrient Gmbh Operandenstapelspeicher und Verfahren zum Betreiben eines Operandenstapelspeichers
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
ES2338534T3 (es) 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005016326A2 (en) 2003-07-11 2005-02-24 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
RS54056B1 (en) 2004-02-06 2015-10-30 Morphosys Ag ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
SI2567976T1 (sl) 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
EP2799451A1 (en) 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
EP3284756B1 (en) 2005-10-12 2021-05-05 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
JP5476122B2 (ja) * 2006-09-26 2014-04-23 ゲンマブ エー／エス Ｃｄ３８発現腫瘍の併用処置法
PL1906602T3 (pl) 2006-09-28 2010-08-31 Nokia Solutions & Networks Gmbh & Co Kg Sterowanie wykrywaniem przeciążenia w systemach HSDPA
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
BRPI0914789A2 (pt) * 2008-06-16 2015-10-20 Immunogen Inc efeitos sinérgicos
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
CN103118706B (zh) * 2010-09-27 2016-05-18 莫佛塞斯公司 抗cd38抗体与来那度胺或硼替佐米用于治疗多发性骨髓瘤和nhl
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38

Also Published As

Publication number Publication date
MX2013003304A (es) 2013-09-26
WO2012041800A1 (en) 2012-04-05
NZ607473A (en) 2014-11-28
US9765152B2 (en) 2017-09-19
KR101912957B1 (ko) 2018-10-29
JP6087283B2 (ja) 2017-03-01
US10308722B2 (en) 2019-06-04
KR20140045288A (ko) 2014-04-16
US8877899B2 (en) 2014-11-04
EP2621531B8 (en) 2017-01-18
JP6231642B2 (ja) 2017-11-15
AU2011310696A1 (en) 2013-03-07
US20160222127A1 (en) 2016-08-04
JP2017048208A (ja) 2017-03-09
SG188345A1 (en) 2013-04-30
PL2621531T3 (pl) 2017-07-31
MX350540B (es) 2017-09-08
EP2621531B1 (en) 2016-11-30
US20130302318A1 (en) 2013-11-14
AU2011310696B2 (en) 2016-06-02
RU2595839C2 (ru) 2016-08-27
LT2621531T (lt) 2017-04-10
US9289490B2 (en) 2016-03-22
EP2621531A1 (en) 2013-08-07
IL224915A (en) 2017-05-29
CN103118706B (zh) 2016-05-18
CA2812631C (en) 2020-12-29
DK2621531T3 (en) 2017-02-27
BR112013006769B1 (pt) 2021-02-02
RU2013113933A (ru) 2014-11-10
HUE031956T2 (en) 2017-08-28
CN103118706A (zh) 2013-05-22
US20150017160A1 (en) 2015-01-15
CA2812631A1 (en) 2012-04-05
PT2621531T (pt) 2017-03-13
ES2617446T3 (es) 2017-06-19
ZA201301232B (en) 2016-05-25
SI2621531T1 (sl) 2017-06-30
US20180022823A1 (en) 2018-01-25
JP2013542191A (ja) 2013-11-21

Similar Documents

Publication Publication Date Title
BR112013006769A2 (pt) combinação sinérgica de um anticorpo específico para cd38
GT201300147A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib
GT201700284A (es) Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina
BR112017004614A2 (pt) terapias de combinação com anticorpos anti-cd38
MX368288B (es) Una combinación de anticuerpos anti-cd38 y melfalán para usarse en el tratamiento de mieloma múltiple.
BR112013027548A2 (pt) cartucho de válvula para uma torneira e conjunto de torneira
BR112013028281A2 (pt) compostos e composições para inibição de nampt
UY4230Q (es) Bocadillo retorcido para mascota
BR112014015826A2 (pt) lactobacillus reuteri 17938 para o desenvolvimento da função cognitiva
BR112013028512A2 (pt) cápsula
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
BR112014025041B8 (pt) Composição farmacêutica
BR112015029774A2 (pt) gaveta para contra golpe para uma válvula e dispositivo
AU2014207408A8 (en) Pharmaceutical compositions comprising nitroxyl donors
CR20140342A (es) Composiciones y métodos para el tratamiento de enfermedades y trastornos hepáticos
BR112014008555A2 (pt) r(+)-n-formil-propargil-aminoindano
TN2014000136A1 (en) Selective androgen receptor modulators
AR104591A1 (es) Piroglutamato de vortioxetina
MX369290B (es) Inhibidores de fbx03.
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CO7190235A2 (es) Composición de película para cubiertas de cápsula dura
BR112013010501A2 (pt) aparelho de barbear ou depilar que compreende uma composição auxiliar moldada para barbeamento ou depilação que compreende uma fonte de piritiona
BR112015005738A2 (pt) formulações orais de angiotensina
BR112012033437A2 (pt) núcleo absorvente
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DAS PRIORIDADES US 61/386,619 DE 27/09/2010 E US 61/486,814 DE 17/05/2011, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDER AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DAS REFERIDAS PRIORIDADES, QUE POSSUEM DEPOSITANTES DIFERENTES DO DEPOSITANTE DA FASE NACIONAL.

B12F Other appeals [chapter 12.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: MORPHOSYS AG (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/09/2011, OBSERVADAS AS CONDICOES LEGAIS.